Papers
Topics
Authors
Recent
Detailed Answer
Quick Answer
Concise responses based on abstracts only
Detailed Answer
Well-researched responses based on abstracts and relevant paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses
Gemini 2.5 Flash
Gemini 2.5 Flash 52 tok/s
Gemini 2.5 Pro 47 tok/s Pro
GPT-5 Medium 18 tok/s Pro
GPT-5 High 13 tok/s Pro
GPT-4o 100 tok/s Pro
Kimi K2 192 tok/s Pro
GPT OSS 120B 454 tok/s Pro
Claude Sonnet 4 30 tok/s Pro
2000 character limit reached

Template-Guided 3D Molecular Pose Generation via Flow Matching and Differentiable Optimization (2506.06305v1)

Published 22 May 2025 in q-bio.BM and cs.LG

Abstract: Predicting the 3D conformation of small molecules within protein binding sites is a key challenge in drug design. When a crystallized reference ligand (template) is available, it provides geometric priors that can guide 3D pose prediction. We present a two-stage method for ligand conformation generation guided by such templates. In the first stage, we introduce a molecular alignment approach based on flow-matching to generate 3D coordinates for the ligand, using the template structure as a reference. In the second stage, a differentiable pose optimization procedure refines this conformation based on shape and pharmacophore similarities, internal energy, and, optionally, the protein binding pocket. We evaluate our approach on a new benchmark of ligand pairs co-crystallized with the same target and show that it outperforms standard docking tools and open-access alignment methods, especially in cases involving low similarity to the template or high ligand flexibility.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Follow-Up Questions

We haven't generated follow-up questions for this paper yet.